Trial · NCT04152200
Results by group57
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 57
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort A: Percent Change in Plasma Oxalate From Baseline to Month 6 | Cohort A: Lumasiran | -33.33 | Standard Error 17.63 | percent change | |
| Cohort B: Percent Change in Pre-dialysis Plasma Oxalate From Baseline to Month 6 | Cohort B: Lumasiran | -42.43 | Standard Error 3.95 | percent change | |
| Cohort B: Percent Change in Plasma Oxalate Area Under the Curve From 0-24 Hours [AUC(0-24)] Between Dialysis Sessions From Baseline to Month 6 | Cohort B: Lumasiran | -41.4 | Standard Error 4.4 | percent change | |
| Absolute Change in Plasma Oxalate From Baseline to Month 6 | Cohort A: Lumasiran | -35.28 | Standard Error 7.40 | μmol/L | |
| Absolute Change in Plasma Oxalate From Baseline to Month 6 | Cohort B: Lumasiran | -48.33 | Standard Error 3.63 | μmol/L | |
| Cohort A: Absolute Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6 | Cohort A: Lumasiran | -0.533 | Standard Error 0.111 | mmol/24hr/1.73m^2 | |
| Cohort A: Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6 | Cohort A: Lumasiran | -10.557 | Standard Error 6.811 | percent change | |
| Cohort A: Absolute Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6 | Cohort A: Lumasiran | -0.1879 | Standard Error 0.0160 | ratio | |
| Cohort A: Percent Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6 | Cohort A: Lumasiran | -39.5136 | Standard Error 9.4294 | percent change | |
| Change in Quality of Life As Assessed by Pediatric Quality of Life Inventory (PedsQL) Total Score From Baseline to Month 6 in Patients >=2 to 18 Years of Age at Time of Informed Consent | Cohort A: Lumasiran | -23.91 | Standard Deviation 9.22 | score on a scale | |
| Change in Quality of Life As Assessed by Pediatric Quality of Life Inventory (PedsQL) Total Score From Baseline to Month 6 in Patients >=2 to 18 Years of Age at Time of Informed Consent | Cohort B: Lumasiran | 0.10 | Standard Deviation 8.52 | score on a scale | |
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort A: Lumasiran | SF-12 Physical Component Score | -1.56 | Standard Deviation 1.19 | score on a scale |
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort B: Lumasiran | SF-12 Physical Component Score | -2.06 | Standard Deviation 6.59 | score on a scale |
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort A: Lumasiran | SF-12 Mental Component Score | -3.88 | Standard Deviation 4.45 | score on a scale |
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort B: Lumasiran | SF-12 Mental Component Score | 1.58 | Standard Deviation 9.61 | score on a scale |
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort A: Lumasiran | Symptoms/Problems of Kidney Disease | -13.64 | Standard Deviation 6.43 | score on a scale |
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort B: Lumasiran | Symptoms/Problems of Kidney Disease | -5.73 | Standard Deviation 7.49 | score on a scale |
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort A: Lumasiran | Effects of Kidney Disease | -15.63 | Standard Deviation 22.10 | score on a scale |
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort B: Lumasiran | Effects of Kidney Disease | -10.16 | Standard Deviation 14.96 | score on a scale |
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort A: Lumasiran | Burden of Kidney Disease | -3.13 | Standard Deviation 4.42 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04152200/results